To establish certain conditions on employment and other work arrangements at the Food and Drug Administration to ensure the safety and security of drugs and devices.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
Restricts FDA employment and post-employment work for people tied to China, Russia, or Iran, and limits access to drug and device review information for FDA reviewers with specified foreign-country ties.
Who Benefits and How
The bill is aimed at reducing foreign influence and information-security risk in FDA drug and device review.
Who Bears the Burden and How
FDA applicants, employees, contractors, and volunteers with covered nationality, family, or employment ties would face eligibility, reporting, termination, access, and post-employment restrictions. FDA managers would need to administer those screening and access-control rules.
Key Provisions
- Bars nationals of China, Russia, or Iran from paid FDA employment or paid service arrangements.
- Requires FDA workers with immediate family members from a foreign country of concern to report that fact.
- Requires termination for failure to make the required family-tie report.
- Imposes a ten-year post-FDA restriction on work for entities based in a foreign country of concern.
- Restricts drug and device review information access for reviewers with covered family ties or prior covered employment.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Restricts FDA employment and post-employment work for people tied to China, Russia, or Iran, and limits access to drug and device review information for FDA reviewers with specified foreign-country ties.
Key Policy Areas
Health, National Security, Government Operations
Primary Purpose
Restricts FDA employment and post-employment work for people tied to China, Russia, or Iran, and limits access to drug and device review information for FDA reviewers with specified foreign-country ties.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- FDA drug and device review programs seeking lower foreign influence and information-security risk
- Patients and regulated markets that rely on trusted FDA review integrity
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- FDA workers and applicants with specified ties to China, Russia, or Iran
- FDA offices responsible for screening, reporting processes, terminations, and access controls
- Entities based in China, Russia, or Iran seeking former FDA workers or FDA-connected labor
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
IntroducedMr. Cotton introduced the following bill; which was read twice …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
FDA drug and device review programs protected from covered foreign influence and information-access risk
FDA employees, applicants, contractors, or volunteers with covered foreign-country ties
Entities based in China, Russia, or Iran seeking FDA current or former personnel
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary"
- → Secretary of Health and Human Services
- "commissioner"
- → Commissioner of Food and Drugs
- "food_and_drug_administration"
- → Food and Drug Administration
Key Definitions
Terms defined in this bill
The People's Republic of China, Russia, or Iran.
An individual's mother, father, sibling, or child.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology